Related Experiment Videos

[Pharmacogenetics of clopidogrel and its clinical significance]

E P Panchenko, A L Komarov

    Kardiologiia
    |October 27, 2012
    PubMed

    Insights

    Clopidogrel

    Area of Science:

    • Pharmacogenetics
    • Clinical Pharmacology
    • Cardiology

    Background:

    • Clopidogrel is a widely used antiplatelet medication.
    • Its efficacy is crucial for patients with ischemic heart disease (IHD).
    • Genetic variations can influence drug metabolism and effectiveness.

    Purpose of the Study:

    • To review the pharmacogenetics of clopidogrel.
    • To evaluate its clinical value and factors affecting efficacy.
    • To compare clopidogrel with other antiplatelet agents.

    Main Methods:

    • Review of major clinical trials and studies on clopidogrel.
    • Analysis of clopidogrel metabolism via CYP2C19 gene polymorphisms.
    • Examination of drug interactions and resistance mechanisms.

    Main Results:

    • Clinical efficacy of clopidogrel is significantly influenced by CYP2C19 gene polymorphisms.
    • Drug interactions, particularly with proton pump inhibitors, can reduce effectiveness.
    • Alternative P2Y12 inhibitors may offer benefits in certain patient groups.

    Conclusions:

    • Understanding clopidogrel pharmacogenetics is vital for personalized antiplatelet therapy.
    • Genetic testing for CYP2C19 status can guide treatment decisions.
    • Strategies to overcome clopidogrel resistance and alternative therapies should be considered.

    Related Concept Videos

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Pharmacogenetics of Drug Metabolism: Overview01:27

    Pharmacogenetics of Drug Metabolism: Overview

    Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
    Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

    Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

    Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
    Pharmacogenetics and Pharmacogenomics: Overview01:29

    Pharmacogenetics and Pharmacogenomics: Overview

    Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...